ACPU
REGN icon

Arrowgrass Capital Partners (US)’s Regeneron Pharmaceuticals REGN Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11,684
Closed -$4.39M – 411
2017
Q4 		$4.39M Buy
11,684
+5,812
+99% +$2.35M 0.04% 321
2017
Q3 		$2.63M Buy
5,872
+811
+16% +$386K 0.02% 425
2017
Q2 		$2.49M Sell
5,061
-8,793
-63% -$3.85M 0.02% 458
2017
Q1 		$5.37M Buy
13,854
+7,117
+106% +$2.64M 0.06% 319
2016
Q4 		$2.47M Buy
6,737
+4,131
+159% +$1.57M 0.03% 344
2016
Q3 		$1.05M Sell
2,606
-250
-9% -$100K 0.01% 359
2016
Q2 		$997K Sell
2,856
-1,782
-38% -$686K 0.01% 343
2016
Q1 		$1.67M Buy
+4,638
New +$1.91M 0.02% 281
2015
Q4 		– Sell
-264
Closed -$123K – 454
2015
Q3 		$123K Buy
+264
New +$142K ﹤0.01% 436

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s REGN Position: Q1 2018 in Review

Arrowgrass Capital Partners (US) sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 11,684 shares — an estimated $4.39M sold.

Arrowgrass Capital Partners (US) first reported a position in REGN in Q3 2015 and held it in 9 quarters. The position peaked at $5.37M in Q1 2017. 620 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

  • Arrowgrass Capital Partners (US) reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 11,684 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $4.39M.
  • Arrowgrass Capital Partners (US) first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 9 quarters.
  • Arrowgrass Capital Partners (US)'s Regeneron Pharmaceuticals position peaked at $5.37M in Q1 2017.
  • 620 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2018, filed 15 May 2018.